Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

Joel Rodríguez-Saldaña, Francisco Padilla-Padilla, Ernesto G Cardona-Muñoz, Yulia Romero-Antonio, María Marcela Arguedas-Núñez, José G Sander-Padilla, Alberto Martínez-Muñoz, Laura A Lugo-Sánchez, Ileana C Rodríguez-Vazquez, Jorge González-Canudas, Joel Rodríguez-Saldaña, Francisco Padilla-Padilla, Ernesto G Cardona-Muñoz, Yulia Romero-Antonio, María Marcela Arguedas-Núñez, José G Sander-Padilla, Alberto Martínez-Muñoz, Laura A Lugo-Sánchez, Ileana C Rodríguez-Vazquez, Jorge González-Canudas

Abstract

Introduction: Cardiovascular diseases are the leading cause of death worldwide. The combination of statins and cholesterol-absorption inhibitors promotes the decrease in risk factors, such as high concentrations of LDL (low-density lipoproteins). The aim of the study was to evaluate changes in the lipid profile and the effect on therapeutic goals, as well as the safety of dyslipidemia patients treated with Rosuvastatin/Ezetimibe (Trezete®).

Materials and methods: A real-world evidence study was conducted with retrospective data collection through a review of clinical records from dyslipidemia patients treated with Trezete® in routine medical practice. Clinical records included results of biochemical markers before treatment and at least one follow up between weeks 8 and 16.

Results: The study included 103 patients' clinical records (55.4% men) with a mean age of 56.0 ± 13.0 years. More than 57% of the patients had mixed dyslipidemia and a median disease progression of 3.1 (IQR, 1.5; 9.1) years. Regarding LDL concentrations, 72.8% of the patients achieved therapeutic goals according to cardiovascular risk (CVR), which was statistically significant. Similarly, 94.1% achieved goals for total cholesterol (<200 mg/dL) and 56.0% for triglycerides (<150 mg/dL), a p value <0.001. No cardiovascular events were observed.

Conclusion: Trezete® shows an important clinical impact on CVR-related target markers during the treatment of dyslipidemia patients. It is relevant to mention that a significant percentage of patients achieved therapeutic goals during the first months of treatment. Fixed-dose combination therapy has shown to be as safe as monotherapy treatment. ClinicalTrials.gov Identifier: NCT04862962.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Copyright © 2022 Joel Rodríguez-Saldaña et al.

Figures

Figure 1
Figure 1
Flowchart of selection and analysis of patient clinical records. ∗ Patients did not have data for this lipid marker.
Figure 2
Figure 2
Proportion of patients who met therapeutic goals according to the degree of cardiovascular risk (CVR) at 8 and 16 weeks, compared to baseline. A p value of <0.05 was taken as statistically significant.
Figure 3
Figure 3
Percentage of patients that achieved therapeutic goals for total cholesterol, triglycerides, and LDL-c at the end of the follow up, compared to baseline. A p value of <0.05 was taken as statistically significant.

References

    1. Roth G. A., Fihn S. D., Mokdad A. H., Aekplakorn W., Hasegawa T., Lim S. S. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bulletin of the World Health Organization . 2011;89(2):92–101. doi: 10.2471/blt.10.079947.
    1. Official Journal of the Federation. Official Mexican Standard NOM-037-SSA2-2012, for the Prevention, Treatment and Control of Dyslipidemias . Mexico City, Mexico: Official Journal of the Federation; 2012.
    1. Garcia-Garcia G., Aviles-Gomez R., Luquin-Arellano V. H., et al. Cardiovascular risk factors in the Mexican population. Renal Failure . 2006;28(8):677–687. doi: 10.1080/08860220600936096.
    1. Secretary H. Guide to the pharmacological treatment of dyslipidemias for the first level of care. Mexican journal of cardiology . 2013;24(3):103–129.
    1. Febriani D., Febriani B. The effect of lifestyle on hypercholesterolemia. Open Public Health Journal . 2018;11(1):526–532. doi: 10.2174/1874944501811010526.
    1. Riccardi G., Vaccaro O., Costabile G., Rivellese A. A. How well can we control dyslipidemias through lifestyle modifications? Current Cardiology Reports . 2016;18(7):p. 66. doi: 10.1007/s11886-016-0744-7.
    1. Pérez de Isla L. dI. L., Pérez de Isla L., Fernández P. L. S., et al. Comments on the 2016 ESC/EAS guidelines for the management of dyslipidemias. Revista Espanola de Cardiologia . 2017;70(2):72–77. doi: 10.1016/j.rec.2017.01.001.
    1. Grundy S. M., Stone N. J., Bailey A. L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation . 2019;139(25):e1082–e1143. doi: 10.1161/CIR.0000000000000625.
    1. Adhyaru B. B., Jacobson T. A. Safety and efficacy of statin therapy. Nature Reviews Cardiology . 2018;15(12):757–769. doi: 10.1038/s41569-018-0098-5.
    1. Luvai A., Mbagaya W., Hall A. S., Barth J. H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology . 2012;6 doi: 10.4137/cmc.s4324.
    1. Cheng J. W. Rosuvastatin in the management of hyperlipidemia. Clinical Therapeutics . 2004;26(9):1368–1387. doi: 10.1016/j.clinthera.2004.09.005.
    1. Battaggia A., Donzelli A., Font M., Molteni D., Galvano A. Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One . 2015;10(4) doi: 10.1371/journal.pone.0124587.e0124587
    1. Zhan S., Tang M., Liu F., Xia P., Shu M., Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database of Systematic Reviews . 2018;11 doi: 10.1002/14651858.CD012502.pub2.CD012502
    1. Barrios V., Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. Expert Review of Clinical Pharmacology . 2021;14(7):793–806. doi: 10.1080/17512433.2021.1925539.
    1. Schiele F., Perez de Isla L., Arca M., Vlachopoulos C. Is it time for single-pill combinations in dyslipidemia? American Journal of Cardiovascular Drugs . 2022;22(3):239–249. doi: 10.1007/s40256-021-00498-2.
    1. Pavia-Lopez A. A., Alcocer-Gamba M. A., Ruiz-Gastelum E. D., et al. Guia de practica clinica mexicana para el diagnostico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerotica. Archivos de Cardiología de México . 2022;92:1–62. doi: 10.24875/ACM.M22000081.
    1. Mach F., Baigent C., Catapano A. L., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal . 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455.
    1. Organization PAHOWH. Cardiovascular risk calculator: hearts en las Américas. 2022. .
    1. Packard C., Chapman M. J., Sibartie M., Laufs U., Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart . 2021;107(17):1369–1375. doi: 10.1136/heartjnl-2020-318760.
    1. Mattiuzzi C., Sanchis-Gomar F., Lippi G. Worldwide burden of LDL cholesterol: implications in cardiovascular disease. Nutrition, Metabolism, and Cardiovascular Diseases . 2020;30(2):241–244. doi: 10.1016/j.numecd.2019.09.008.
    1. Baigent C., Landray M. J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet . 2011;377(9784):2181–2192.
    1. Cannon C. P., Blazing M. A., Giugliano R. P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine . 2015;372(25):2387–2397. doi: 10.1056/nejmoa1410489.
    1. Kim K. J., Kim S. H., Yoon Y. W., et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (multicenter randomized study of ROsuvastatin and eZEtimibe) Cardiovascular Therapy . 2016;34(5):371–382. doi: 10.1111/1755-5922.12213.
    1. Hong S. J., Jeong H. S., Ahn J. C., et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-rosette (ildong rosuvastatin & ezetimibe for hypercholesterolemia) randomized controlled trial. Clinical Therapeutics . 2018;40(2):226–241.e4. doi: 10.1016/j.clinthera.2017.12.018.
    1. Ballantyne C. M., Hoogeveen R. C., Raya J. L., et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis . 2014;232(1):86–93. doi: 10.1016/j.atherosclerosis.2013.10.022.
    1. Guyton J. R., Betteridge D. J., Farnier M., et al. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diabetes and Vascular Disease Research . 2011;8(2):160–172. doi: 10.1177/1479164111406457.
    1. Vattimo A. C. A., Fonseca F. A. H., Morais D. C., et al. Efficacy and tolerability of a fixed-dose combination of rosuvastatin and ezetimibe compared with a fixed-dose combination of simvastatin and ezetimibe in Brazilian patients with primary hypercholesterolemia or mixed dyslipidemia: a multicenter, randomized trial. Current Therapeutic Research . 2020;93 doi: 10.1016/j.curtheres.2020.100595.100595

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj